What are the best treatments for Dravet Syndrome?

Dravet Syndrome is a complex, treatment-resistant form of epilepsy that requires a highly personalized, multi-drug approach to manage seizure frequency and developmental outcomes. Current standards for Dravet Syndrome management prioritize a combination of specific anti-seizure medications (ASMs) alongside the avoidance of sodium channel blockers, which can worsen seizure activity in these patients.

What are the primary medical treatments for Dravet Syndrome?

Because Dravet Syndrome is typically resistant to traditional monotherapy, neurologists often prescribe a combination of medications to achieve the best possible seizure control. It is critical to note that certain medications, particularly sodium channel blockers like carbamazepine, phenytoin, and lamotrigine, are generally contraindicated as they may exacerbate seizures in individuals with Dravet Syndrome. Current pharmacological management often includes:

• Stiripentol (Diacomit): Often used as an add-on therapy, this is a cornerstone treatment for Dravet Syndrome.


• Cannabidiol (Epidiolex): A purified, plant-derived cannabidiol approved specifically for the treatment of seizures associated with Dravet Syndrome.


• Fenfluramine (Fintepla): A medication that has shown significant efficacy in reducing convulsive seizure frequency in clinical trials for Dravet Syndrome.


• Valproate (Depakene/Depakote) and Clobazam (Onfi): Frequently used as adjunctive therapies to stabilize seizure activity.

What non-pharmacological interventions are used?

Beyond medication, a multidisciplinary approach is essential for supporting the developmental and physical needs of those living with Dravet Syndrome. A ketogenic diet—a high-fat, low-carbohydrate, and adequate-protein diet—is often recommended by metabolic specialists as a non-pharmacological intervention that can help reduce seizure frequency in some patients. Furthermore, physical, occupational, and speech therapies are vital to address the neurodevelopmental delays, ataxia, and motor deficits commonly observed in this patient population.

What is the multidisciplinary approach to care?

Managing Dravet Syndrome effectively requires a coordinated team of healthcare professionals. With 453 people with Dravet Syndrome currently sharing their experiences on DiseaseMaps.org, it is clear that a robust support network is vital. The care team should ideally include:

1. Epileptologist: A neurologist specializing in epilepsy, who serves as the primary manager of the seizure treatment plan.


2. Genetic Counselor: To help families understand the SCN1A gene mutation and recurrence risks.


3. Physical and Occupational Therapists: To manage gait disturbances and improve daily living skills.


4. Neuropsychologist: To monitor cognitive development and behavioral health.


5. Dietitian: Specialized in the implementation and monitoring of medical diets like the ketogenic or modified Atkins diet.

Are there emerging treatments for Dravet Syndrome?

The landscape for Dravet Syndrome research is rapidly evolving. Current clinical trials are investigating precision medicine approaches, including gene therapies and antisense oligonucleotides (ASOs), which aim to address the underlying genetic cause rather than just the symptoms. Researchers are also looking into long-term outcomes to better understand how early intervention affects the quality of life for those with Dravet Syndrome.

Next steps

• Consult a board-certified epileptologist to review your current medication regimen and ensure sodium channel blockers are avoided.


• Connect with the community at DiseaseMaps.org to learn from the 453 members who have shared their personal experiences with Dravet Syndrome.


• Request a referral to a genetic counselor to discuss the specific genetic findings associated with your diagnosis.


• Maintain a detailed seizure diary to track medication effectiveness and potential triggers.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; all treatment decisions must be made in consultation with your personal healthcare team.

References

• NIH GARD: Dravet Syndrome Overview (rarediseases.info.nih.gov)


• Orphanet: Clinical practice guidelines for the management of Dravet Syndrome (orpha.net)


• Dravet Syndrome Foundation: Treatment and Research Resources (dravetfoundation.org)


• OMIM: Dravet Syndrome (SCN1A-related) entry (omim.org)